1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Nordic Cancer Targeted Therapy Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Nordic Cancer Targeted Therapy Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Nordic Cancer Targeted Therapy Market Regional Analysis
6.2 Nordic Cancer Targeted Therapy Market Revenue 2021-2031 (US$ Million)
6.3 Nordic Cancer Targeted Therapy Market Forecast Analysis
7. Nordic Cancer Targeted Therapy Market Analysis – by Therapy Type
7.1 Monoclonal Antibodies
- 7.1.1 Overview
- 7.1.2 Monoclonal Antibodies: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Tyrosine Kinase Inhibitors
- 7.2.1 Overview
- 7.2.2 Tyrosine Kinase Inhibitors: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Immune Checkpoint Inhibitors
- 7.3.1 Overview
- 7.3.2 Immune Checkpoint Inhibitors: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Cancer Vaccines
- 7.4.1 Overview
- 7.4.2 Cancer Vaccines: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Gene Therapy
- 7.5.1 Overview
- 7.5.2 Gene Therapy: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Other Therapy Types
- 7.6.1 Overview
- 7.6.2 Other Therapy Types: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8. Nordic Cancer Targeted Therapy Market Analysis – by Indication
8.1 Blood Cancer
- 8.1.1 Overview
- 8.1.2 Blood Cancer: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Lung Cancer
- 8.2.1 Overview
- 8.2.2 Lung Cancer: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Breast Cancer
- 8.3.1 Overview
- 8.3.2 Breast Cancer: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Colorectum Cancer
- 8.4.1 Overview
- 8.4.2 Colorectum Cancer: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Prostate Cancer
- 8.5.1 Overview
- 8.5.2 Prostate Cancer: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Stomach Cancer
- 8.6.1 Overview
- 8.6.2 Stomach Cancer: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.7 Cervical Cancer
- 8.7.1 Overview
- 8.7.2 Cervical Cancer: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.8 Liver and Intrahepatic Bile Duct Cancer
- 8.8.1 Overview
- 8.8.2 Liver and Intrahepatic Bile Duct Cancer: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.9 Thyroid Cancer
- 8.9.1 Overview
- 8.9.2 Thyroid Cancer: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.10 Other Indications
- 8.10.1 Overview
- 8.10.2 Other Indications: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9. Nordic Cancer Targeted Therapy Market Analysis – by End User
9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Online Stores
- 9.3.1 Overview
- 9.3.2 Online Stores: Nordic Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
10. Nordic Cancer Targeted Therapy Market – Nordic Analysis
10.1 Overview
10.2 Nordic
- 10.2.1 Nordic Cancer Targeted Therapy Market Breakdown, by Key
Country, 2025 and 2031 (%)
- 10.2.1.1 Nordic Cancer Targeted Therapy Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 Sweden:
Nordic Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.1.1 Sweden: Nordic Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.1.2 Sweden: Nordic Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.1.3 Sweden: Nordic Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.2 Denmark:
Nordic Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.2.1 Denmark: Nordic Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.2.2 Denmark: Nordic Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.2.3 Denmark: Nordic Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.3 Norway:
Nordic Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.3.1 Norway: Nordic Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.3.2 Norway: Nordic Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.3.3 Norway: Nordic Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.4 Finland:
Nordic Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.4.1 Finland: Nordic Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.4.2 Finland: Nordic Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.4.3 Finland: Nordic Cancer Targeted Therapy Market Breakdown, by End User
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Astellas Pharma Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Eli Lilly and Co
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Novartis AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Merck KGaA
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Johnson & Johnson
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 AstraZeneca
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Pfizer Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Bristol Myers Squibb
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 F. Hoffmann-La Roche Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 AbbVie
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations